Post-marketing safety monitoring of a new group B meningococcal vaccine in New Zealand, 2004-2006.
Hum Vaccin
; 3(5): 196-204, 2007.
Article
em En
| MEDLINE
| ID: mdl-17660718
ABSTRACT
New Zealand introduced a new outer membrane vesicle vaccine in 2004 to combat an epidemic of group B meningococcal disease. An Independent Safety Monitoring Board oversaw intensive safety monitoring, which included hospital surveillance, health professional reporting (passive and active) and mortality monitoring. With over three million doses administered to individuals aged under 20 years, the monitoring results provide consistent evidence supporting the vaccine's safety.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Vigilância de Produtos Comercializados
/
Vacinas Meningocócicas
/
Neisseria meningitidis Sorogrupo B
/
Meningite Meningocócica
Limite:
Humans
País/Região como assunto:
Oceania
Idioma:
En
Revista:
Hum Vaccin
Assunto da revista:
ALERGIA E IMUNOLOGIA
Ano de publicação:
2007
Tipo de documento:
Article
País de afiliação:
Nova Zelândia